Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 25 or more amino acid residues in defined sequence
Reexamination Certificate
2007-02-06
2007-02-06
Chan, Christina (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
25 or more amino acid residues in defined sequence
C530S325000, C530S326000, C530S327000, C530S806000, C530S868000
Reexamination Certificate
active
10378479
ABSTRACT:
The invention provides methods for identifying peptide epitopes that activate CD4+ T cells involved in the pathogenesis of diseases, e.g., autoimmune diseases, susceptibility to which is determined by expression of particular class II MHC genes. The invention includes peptides derived from the IA-2 polypeptide by such a method, altered peptide ligands, and methods of therapy involving the use of altered peptide ligands.
REFERENCES:
patent: 5827516 (1998-10-01), Urban et al.
patent: WO 94/04171 (1994-03-01), None
patent: WO 99/55849 (1999-11-01), None
Janeway et al. Immunobiology 4rth Edition (1994) Garland Press USA, p. 568.
Atkinson et al., “64 000 Mrautoantibodies as predictors of insulin-dependent diabetes,” The Lancet 335:1357-60, 1990.
Atkinson et al., “Response of peripheral-blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes,” The Lancet 339:458-59, 1992.
Atkinson et al., “Cellular Immunity to a Determinant Common to Glutamate Decarboxylase and Coxsackie Virus in Insulin-dependent Diabetes,” J. Clin. Invest. 94:2125-2129, 1994.
Baekkeskov et al., “Antibodies to a 64,000 MrHuman Islet Cell Antigen Precede the Clinical Onset of Insuli dependent Diabetes,” J. Clin. Invest. 79:926-934, 1987.
Baekkeskov et al., “Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase,” Nature 347:151-156, 1990.
Baekkeskov et al., “Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins,” Nature 298:167-169, 1982.
Bingley et al., “Prediction of IDDM in the General Population, Strategies Based on Combinations of Autoant body Markers,” Diabetes 46:1701-1710, 1997.
Bingley et al., “Perspectives in Diabetes, Can We Really Predict IDDM?” Diabetes 42:213-20, 1993.
Bonifacio et al., “Identification of Protein Tyrosine Phosphatase-Like IA2 (Islet Cell Antigen 512) as the Insulin-Dependent Diabetes-Related 37/40K . . . Antibodies,” The Journal of Immunology 155:5419-5426, 1995.
Bonifacio et al., “IA-2 (Islet Cell Antigen 512) Is the Primary Target of Humoral Autoimmunity Against Typ Diabetes-Associated Tyrosine Phosphatase Autoantigens,” The Journal of Immunology 161:2648-2654, 1998.
Giorda et al., “Glutamic acid decarboxylase expression in islets and brain,” The Lancet 338:1469-70, 1991.
Castano et al., “Characterization of Insulin Autoantibodies in Relatives of Patients with Type I Diabetes,” Diabetes 42:1202-209, 1993.
Castano et al., “Type-I Diabetes: A Chronic Autoimmune Disease of Human, Mouse, and Rat,” Annu. Rev. Immunol. 8:647-79, 1990.
Chicz et al., “Specificity and Promiscuity among Naturally Processed Peptides Bound to HLA-DR Alleles,” J. Exp. Med. 178:27-47, 1993.
Chicz et al., “HLA-DP2—Self Peptide Sequences and Binding Properties,” J. of Immunology 159:4935-4942, 1997.
Chicz et al., “Analysis of MHC-presented peptides: applications in autoimmunity and vaccine development,” Immunology Today 15(4):155-160, 1994.
Chicz et al., “Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size,” Nature 358:764-768, 1992.
Chilson et al., “Mitogenic lectins bind to the antigen receptor on human lymphocytes,” Eur. J. Immunol. 19:389-396, 1989.
Christie et al., “Distinct Antibody Specificities to a 64-kD Islet Cell Antigen in Type 1 Diabetes as Revealed by Trypsin Treatment,” J. Exp. Med. 172:789-794, 1990.
Christie et al., “Antibodies to Islet 37k Antigen, But Not to Glutamate-Decarboxylase, Discriminate Rapid Progression to IDDM in Endocrine Autoimmunity,” Diabetes 43:1254-1259, 1994.
Combadiere et al., “Selective Induction of Apoptosis in Mature T Lymphocytes by Variant T Cell Receptor Ligands,” The J. of Experimental Medicine 187(3):349-355, 1998.
Congia et al., “T cell epitopes of insulin defined in HLA-DR4 transgenic mice are derived from preproinsulin and proinsulin,” Proc. Natl. Acad. Sci. USA 95:3833-3838, 1998.
Das et al., “Autopathogenic T Helper Cell Type 1 (Th1) and Protective Th2 Clones Differ in Their Recognition of the Autoantigenic Peptide of Myelin Proteolipid Protein,” J. Exp. Med. 186(6):867-876, 1997.
Davies et al., “A genome-wide search for human type 1 diabetes susceptibility genes,” Nature 371:130-36,1994.
De Aizpurua et al., “Glutamic acid decarboxylase autoantibodies in preclinical insulin-dependent diabetes,” Proc. Natl. Acad. Sci. USA 89:9841-9845, 1992.
Endi et al., “Identification of Naturally Processed T Cell Epitopes from Glutamic Acid Decarboxylase Presented . . . Patients,” J. Clin. Invest. 99(10):2405-2415, 1997.
Germain, “MHC-Dependent Antigen Processing and Peptide Presentation: Providing Ligands for T Lymphocyte Activation,” Cell 76(2):287-99, 1994.
Gorga et al., “Purification and Characterization of Class II Histocompatibility Antigens from a Homozygous Human 8 Cell Line,” The J. of Biological Chemistry 262(33):16087-16094, 1987.
Honeyman et al., “T-Cell Epitopes in Type 1 Diabetes Autoantigen Tyrosine Phosphatase IA-2: Potential for Mimicry with Rotavirus and Other Environmental Agents,” Molecular Medicine 4:231-239, 1998.
Honeyman et al., “Neural network-based prediction of candidate T-cell epitopes,” Nature Biotechnology 16:966-969, 1998.
Kawasaki et al., “Evaluation of Islet Cell Antigen (ICA) 512/IA-2 Autoantibody Radioassays Using Overlapping ICA512/IA-2 Constructs,” JCE & M 82(2):375-380, 1997.
Khalil et al., “Dose Effect of Cis- and Trans-Encoded HLA-DQαβ Heterodimers in IDDM Susceptibility,” Diabetes 41:378-384, 1992.
Krebs et al., “Substituting Nonpeptidic Spacers for the T Cell Receptor-binding Part of Class I Major Histocompatibility Complex-binding Peptides,” The J. of Biological Chemistry 273(30):19072-19079, 1998.
Kuglin et al., “Antibodies to Proinsulin and Insulin as Predictive Markers of Type 1 Diabetes,” Diabetic Medicine 7:310-314, 1990.
Kwok et al., “HLA-DQB1 Codon 57 Is Critical for Peptide Binding and Recognition,” J. Exp. Med 183:1253-1258, 1996.
Lohmann et al., “Immunodominant epitopes of glutamic acid decarboxylase 65 and 67 in insulin-dependent diabetes mellitus,” The Lancet 343:1607-1608, 1994.
Marsh, “HLA class II region sequences,” Tissue Antigens 51:467-507, 1998.
Nepom et al., “Perspectives in Diabetes: Molecular Basis for HLA-DQ Associations with IDDM,” Diabetes 47: 1177-1184, 1998.
Nep{dot over (o)}m, “Class II Antigens and Disease Susceptibility,” Annu. Rev. Med. 46:17-25, 1995.
Nicholson et al., “Heteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: Implications for autoimmunity,” Proc. Natl. Acad. Sci. USA 95:264-269, 1998.
Nicholson et al., “An Altered Peptide Ligand Mediates Immune Deviation and Prevents Autoimmune Encephalomyelitis,” Immunity 3:397-405, 1995.
Nicholson et al., “A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis . . . antigens,” Proc. Natl. Acad. Sci. USA 94:9279-9284, 1997.
Nicholson et al., “Manipulation of the Th1/Th2 balance in autoimmune disease,” Current Opinion in Immunology 8:837-842, 1996.
Patel et al., “Identification of immunodominant T cell epitopes of human glutamic acid decarboxylase 65 by using HLA-DR . . . mice,” Proc. Natl. Acad. Sci. USA 94:8082-8087, 1997.
Payton et al., “Relationship of the 37,000- and 40,000-MrTryptic Fragments of Islet Antigens in Insulin-dependent Diabetes . . . (ICA512),” J. Clin. Invest. 9
Chicz Roman M.
Peakman Mark
Chan Christina
Fish & Richardson P.C.
King's College London
MGI Pharma Biologics, Inc.
VanderVegt F. Pierre
LandOfFree
Peptide epitopes recognized by disease promoting CD4+ T... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide epitopes recognized by disease promoting CD4+ T..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide epitopes recognized by disease promoting CD4+ T... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3840164